Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.
Xuyang SongRobin Kate KelleyAnis A KhanNathan StandiferDiansong ZhouKyoungSoo LimRajesh KrishnaLu LiuKun WangPatricia McCoonAlejandra NegroPhilip HeMegan GibbsJohn F KurlandGhassan K Abou-AlfaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our findings support novel insights into tremelimumab pharmacokinetics and exposure-response relationships in HCC and support the clinical utility of the STRIDE regimen in patients with uHCC.